1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors
Condition: Solid
Sponsor: Boehringer Ingelheim
Full Title
Protocol 1403-0002: A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors
Study Treatment
MDM2 inhibitor BI 907828 + anti PD-1 antibody ezabenlimab